Breaking: FDA Schedules Advisory Committee Meetings to Review Peptide Restrictions
Key Takeaways
- FDA has scheduled PCAC meetings for July 23–24, 2026 to review 7 peptides
- BPC-157, TB-500, KPV, MOTS-C, Semax, Selank, and DSIP are on the agenda
- This is the first concrete regulatory step toward reclassification
- A second review covering additional peptides is expected by February 2027
In a significant development for the peptide research community, the FDA published a Federal Register notice on April 16, 2026, officially scheduling meetings of the Pharmacy Compounding Advisory Committee (PCAC) for July 23–24, 2026. The committee will evaluate whether several peptides currently restricted under Category 2 should be made available for compounding under Section 503A.
What’s Being Reviewed
The two-day meeting will cover seven peptide compounds across both sessions.
July 23, 2026 — Session 1
| Peptide | Use Evaluated |
|---|---|
| BPC-157 | Ulcerative colitis |
| KPV | Wound healing, inflammatory conditions |
| TB-500 | Wound healing |
| MOTS-C | Obesity, osteoporosis |
July 24, 2026 — Session 2
| Peptide | Use Evaluated |
|---|---|
| Emideltide (DSIP) | Sleep regulation |
| Semax | Cognitive function |
| Selank | Anxiety, immune modulation |
Why This Matters
This advisory committee meeting is the first concrete regulatory step following HHS Secretary Robert F. Kennedy Jr.’s February 2026 announcement that approximately 14 of the 19 peptides placed on the Category 2 restricted list in 2023 would be reviewed for reclassification back to Category 1.
On April 15, 2026, Secretary Kennedy directed the FDA to remove all 12 peptides from Category 2. Each will go through the PCAC for independent expert review, beginning with this July meeting.
If reclassified to Category 1, these peptides would become eligible for compounding by licensed 503A pharmacies under valid physician prescriptions — restoring the regulated access pathway that existed before the 2023 restrictions.
What This Does NOT Mean
Reclassification ≠ FDA approval. Category 1 status allows compounding while under evaluation. These peptides have not completed the clinical trial process required for an NDA or BLA. They require physician prescriptions and are not available over the counter.
Quality, purity, and proper handling remain critical regardless of regulatory status. Sourcing from reputable suppliers with transparent testing protocols is essential.
The Bigger Picture
The 2023 Category 2 restrictions pushed many consumers toward unregulated gray market sources — a concern central to the argument for reversing the restrictions. Restoring regulated access through licensed pharmacies with USP 797/795 compliance standards represents a safer framework for both clinical and research applications.
A second PCAC meeting is expected by February 2027 to review the remaining peptides under consideration.
At Neogenesis BioLabs, we remain committed to providing research-grade peptides with full third-party testing and certificates of analysis. We will continue monitoring these developments and providing updates as the July meetings approach.
Sources
- U.S. Federal Register — Pharmacy Compounding Advisory Committee; Notice of Meeting, Document No. 2026-07361, published April 16, 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
- BioPharma Dive — FDA moves toward easing restrictions on certain peptides, April 16, 2026. https://www.biopharmadive.com/news/fda-peptides-rfk-advisory-committee-restrictions/817685/
- The Hill — FDA to weigh lifting restrictions on some MAHA-favored peptides, April 15, 2026. https://thehill.com/policy/healthcare/5832457-fda-considers-peptide-access/
- U.S. Food & Drug Administration — Bulk Drug Substances Used in Compounding Under Section 503A. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a
Last updated: April 17, 2026